Skip to main content
Premium Trial:

Request an Annual Quote

Monogram Biosciences to Use eTag Assays in Cancer Biomarker Study for Merck

NEW YORK, Oct. 24 (GenomeWeb News)  Monogram Biosciences will use its eTag assays to conduct a cancer biomarker study on Erbitux (cetuximab), Merck KGaA's IgG1 monoclonal antibody, Monogram said today.

 

Monogram, formerly ViroLogic, will test formalin-fixed, paraffin-embedded tumor samples from patients with colorectal cancer before they are treated with Erbitux, which specifically targets the epidermal growth factor receptor found on many cancer cells. After testing the samples for EGFR-containing receptor dimers, both companies will compare Monogram's predictions of response based with actual clinical outcomes.

 

Merck KGaA will make payments to Monogram for the project. Other financial details were not disclosed.

 

Monogram said that it has used its eTag assays to identify activated drug targets or signaling pathways and their correlation with drug activity in nine similar collaborations with pharmaceutical and biotechnology companies.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.